重组人促红素注射液联合左卡尼汀注射剂治疗终末期肾病肾性贫血的疗效及对患者心功能的影响

Effect of Recombinant Human Erythropoietin Injection Combined with Levocarnitine Injection in the Treatment of Renal Anemia in Patients with End-stage Renal Disease and its Effect on Cardiac Function

目的研究重组人促红素注射液(rhEPO)联合左卡尼汀注射剂(LC)治疗终末期肾病(ESRD)肾性贫血的疗效及对患者心功能的影响。方法以2019年6月-2022年6月广信区中医院收治的50例ESRD肾性贫血患者为研究对象,采用随机数字表法分为对照组(20例)和观察组(30例)。对照组给予rhEPO治疗,观察组应用rhEPO联合LC治疗,比较两组贫血治疗效果、血常规指标[红细胞(RBC)、血红蛋白(Hb)、红细胞比容(HCT)]、炎症指标[超敏C反应蛋白(hs-CRP)、白介素6(IL-6)]、心功能指标[血清脑钠肽(BNP)、左心室射血分数(LVEF)]及不良反应。结果观察组贫血治疗总有效率高于对照组(P<0.05);两组治疗后RBC、Hb、HCT水平均高于治疗前,且观察组RBC、Hb、HCT高于对照组(P<0.05);两组治疗后hs-CRP、IL-6均低于治疗前,且观察组hs-CRP、IL-6低于对照组(P<0.05);两组治疗后BNP水平低于治疗前,LVEF高于治疗前,且观察组BNP水平低于对照组,LVEF高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论rhEPO联合LC治疗ESRD肾性贫血疗效突出,可有效纠正患者的血常规指标,下调体内炎症反应,同时改善心功能,且不增加不良反应,安全性良好。

Objective To study the therapeutic effect of recombinant human erythropoietin injection(rhEPO)combined with levocarnitine injection(LC)on renal anemia in patients with end-stage renal disease(ESRD)and its effect on cardiac function.Methods A total of 50 patients with ESRD renal anemia admitted to Guangxin District Hospital of Traditional Chinese Medicine from June 2019 to June 2022 were divided into control group(20 patients)and observation group(30 patients)by random number table method.The control group was treated with rhEPO,and the observation group was treated with rhEPO combined with LC.The therapeutic effect of anemia,blood routine indexes[red blood cell(RBC),hemoglobin(Hb),hematocrit(HCT)],inflammatory indexes[high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)],cardiac function indexes[serum brain natriuretic peptide(BNP),left ventricular ejection fraction(LVEF)]and adverse reactions were compared between the two groups.Results The total effective rate of anemia treatment in the observation group was higher than that in the control group(P<0.05).The levels of RBC,Hb and HCT in the two groups after treatment were higher than those before treatment,and the levels of RBC,Hb and HCT in the observation group were higher than those in the control group(P<0.05).After treatment,hs-CRP and IL-6 in the two groups were lower than those before treatment,and hs-CRP and IL-6 in the observation group were lower than those in the control group(P<0.05).After treatment,the BNP level of the two groups was lower than that before treatment,LVEF was higher than that before treatment,and the BNP level of the observation group was lower than that of the control group,LVEF was higher than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion rhEPO combined with LC is effective in the treatment of ESRD renal anemia,which can effectively correct the blood routine indexes,down-regulate the inflammatory response in vivo,and improve the cardiac function without increasing adverse reactions,with good safety.